Cure My Disease

Don't miss your cure!

 Log in / Sign up

New injections aim to shrink Hard-to-Treat skin tumors

NCT ID NCT07227350

Recruiting now Disease control Sponsor: Philogen S.p.A. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This phase 2 trial tests three experimental drugs—L19IL2, L19TNF, or a combination—injected directly into skin tumors for people with advanced basal cell carcinoma who cannot have surgery or radiation. About 180 participants will receive weekly injections for four weeks and be followed for up to three years. The goal is to see if these drugs can shrink or control the tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
L19IL2 and L19TNF (immune-targeting drugs injected directly into tumors)
What this could lead to
If successful, this could offer a new treatment option for people with advanced basal cell skin cancer who cannot have surgery or radiation.
What could go wrong
This is an early phase 2 trial with only 180 participants, so results may not apply to everyone. The drugs are injected directly into tumors, which may cause local side effects like pain or swelling, and the treatment may not shrink tumors in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BASAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

basal cell carcinoma skin basal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED BASAL CELL CARCINOMA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Andreas Syngros Hospital Of Venereal And Dermatological Diseases

    NOT_YET_RECRUITING

    Athens, 16121, Greece

  • Azienda Ospedaliero-Universitaria Senese

    RECRUITING

    Siena, 53100, Italy

  • Charite Universitaetsmedizin Berlin KöR

    RECRUITING

    Berlin, 10117, Germany

  • Duke University Medical Center

    RECRUITING

    Durham, North Carolina, 27710, United States

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    RECRUITING

    Roma, 00168, Italy

  • H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc.

    RECRUITING

    Tampa, Florida, 33612, United States

  • Hospital Clinic De Barcelona

    RECRUITING

    Barcelona, 08036, Spain

  • Humanitas Mirasole S.p.A.

    RECRUITING

    Rozzano, 20089, Italy

  • IRCCS Istituto Nazionale Tumori Fondazione Pascale

    RECRUITING

    Naples, 80131, Italy

  • The Ohio State University Wexner Medical Center Clinical Laboratories

    NOT_YET_RECRUITING

    Columbus, Ohio, 43210, United States

  • The University of Texas MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • Universitaetsklinikum Augsburg

    RECRUITING

    Augsburg, 86179, Germany

  • Universitaetsklinikum Essen AöR

    RECRUITING

    Essen, 45147, Germany

  • Universitaetsklinikum Halle (Saale) AöR

    RECRUITING

    Halle, 06120, Germany

  • Universitaetsklinikum Schleswig-Holstein AöR

    RECRUITING

    Kiel, 24105, Germany

  • Universitaetsklinikum Tuebingen AöR

    RECRUITING

    Tübingen, 72076, Germany

  • University Hospitals Cleveland Medical Center

    NOT_YET_RECRUITING

    Cleveland, Ohio, 44106, United States

  • Winship Cancer Institute, Emory University

    RECRUITING

    Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.